Tax Partner Kevin Glenn Joins King & Spalding's New York Office

NEW YORK, NY—(Marketwired – February 12, 2018) – King & Spalding today announced that Kevin Glenn has joined as a partner in the New York office. Glenn, a former partner at KPMG, joins the firm's Corporate, Finance and Investments practice group, which includes the firm's tax practice, to provide U.S. tax advice to U.S. and foreign multinational companies on cross–border financing, joint venture, and M&A transactions.

Glenn spent over 25 years at KPMG, where clients sought him out for his extensive experience in supply chain planning, post–merger global integration, cash repatriation, and foreign tax credit planning. His practice cuts across multiple industries including consumer products, financial institutions, automotive, retail and pharmaceutical companies.

“As the firm expands its transactional practice in New York and London, Kevin's insight and his relationships with tax executives, CFOs and in–house tax counsel around the world will be key to our ability to serve our clients,” said Todd Holleman, head of the firm's Corporate, Finance and Investments practice.

“Kevin is a top–flight U.S. tax lawyer, with deep experience in the most topical tax area, international transactional planning,” added Hap Shashy, a former IRS Chief Counsel who is a senior partner in the firm's tax practice. “We are very happy to have him on board and look forward to working with him.”

While at KPMG, Glenn held a number of upper management positions, including partner–in–charge of U.S. International Tax and most recently was a senior technical partner based in its National Tax Practice, serving that firm's largest clients dealing with complex cross–border tax issues. Glenn is a member of the bar in New York and New Jersey and is also a licensed Certified Public Accountant in each state.

“Kevin's high–level transactional experience makes him a great addition to the firm's tax practice and to the New York office,” said Ed Kehoe who heads the firm's New York office. “We are thrilled to welcome him to the firm.”

Since 2010, Glenn has been a part–time adjunct professor of law at Seton Hall University School of Law. He received his undergraduate degree from Montclair State University, his J.D. from Rutgers University School of Law, and his LL.M. in taxation from New York University School of Law.

“King & Spalding's focus on expanding its domestic and global M&A practice, its talented team of senior and junior tax lawyers, and the momentum of its financial performance over the past 10 years make this an exciting next step for me professionally,” Glenn said. “I can't wait to partner with the other lawyers of the Corporate, Finance and Investments group to grow the practice.”

About King & Spalding
Celebrating more than 130 years of service, King & Spalding is an international law firm that represents a broad array of clients, including half of the Fortune Global 100, with over 1,000 lawyers in 20 offices in the United States, Europe, the Middle East and Asia. The firm has handled matters in over 160 countries on six continents and is consistently recognized for the results it obtains, uncompromising commitment to quality, and dedication to understanding the business and culture of its clients. More information is available at www.kslaw.com.

Image Available: http://www.marketwire.com/library/MwGo/2018/2/12/11G149893/Images/Glenn_Kevin–4f16bbdbaa7fbc838e943cfb4594e8b4.jpg

CoreMedia's 25th Raises $345,000 For Charity

NEW YORK, NY—(Marketwired – February 12, 2018) – More than 900 attendees, including ad agency clients, advertisers strategic partners and friends, jammed New York's famed Gotham Hall on January 18 to celebrate CoreMedia Systems' 25th Anniversary charity event, which raised more than $345,000 for the Good Tidings Foundation.

The centerpiece of the evening, titled Response Responsibility, were live performances by Platinum recording artists Marc Roberge of O|A|R and Questlove, a personal appearance by C.C. Sabathia and a video cameo by Kenny Loggins. They were joined by Natasha Diggs to entertain an enthusiastic crowd that alternately danced and networked for more than five hours at Gotham Hall.

CoreMedia celebrated its 20th Anniversary in 2012, raising over $250,000 for the San Francisco–based Good Tidings Foundation.

“We knew that to make this evening have an appreciable difference for Good Tidings, we would have to set the bar quite high. Our goal was to increase our 2012 fundraising by 30%”, said Glenn DeKraker, Founder and CEO of CoreMedia. “Thanks to the incredible generosity of our sponsors, we were able to hand Good Tidings Founder Larry Harper a check for $345,000. The evening wildly exceeded our expectations.”

Good Tidings announced that proceeds from the evening would fund the construction of a new Leroy Neiman Art Studio in conjunction with the Muhammed Ali Foundation at his high school in Louisville, KY, two new recording studios to be built in Santa Barbara, CA in conjunction with Grammy Award–winning artist Loggins and teaming with longtime supporter C.C. Sabathia for a complete renovation of the Boys and Girls Club in the Bronx, NY.

Among the event sponsors included: Horizon Next, GroupM, Pathway Media Group, WideOrbit, Eicoff, Icon Media Direct, 4C Analytics, Active International, Performics, Diray Media, Allscope Direct, Strata, InterMedia, IPS, ICON International, DISH, Feld Direct, Sling, Chief Media, Kantar Media, Strategic Media, Nielsen Sigma, The Cross Agency, Cadent Network, Discovery Channel, Brooks Roman, Media Monitors, Comcast Technology Solutions.

About CoreMedia – CoreMedia Systems develops and supports CoreDirect, the industry's most widely used direct response media management software. The system is used by more than 125 direct response agencies and marketers to plan, buy, manage, measure and optimize direct response media campaigns.

Corporate Website: www.coremedia–systems.com Event Website: www.ResponseResponsibility.org

About Good Tidings Foundation – Good Tidings Foundation, a 501(c)(3) children's charity founded in 1995, supports art, education, athletics, and dreams for youth from communities in need. Good Tidings has created over 180 projects for deserving youth that strengthen young people's physical health, creativity, and intellectual growth. For more information, visit www.goodtidings.org.

FirstCryptoBank Adds Social Activity Features for Member-to-Member Digital Asset Swaps

FORT LAUDERDALE, FL—(Marketwired – February 12, 2018) – Security First International Holdings, Inc. (OTC PINK: SCFR), a company focused on providing innovative financial payment products and services to consumers globally, today introduced new social features to FirstCryptoBank. The new features will assist in member–to–member communication for decentralized cryptocurrency swaps.

Members will now have the ability to post swap offers on their profile, direct message with other members for swap arrangements and follow high performing members.

Consumers can visit http://firstcryptobank.io register and enroll into the company's members community and begin swapping any cryptocurrency free of charge.

“Our new features allow members to explore new opportunities by providing discovery and communication with other cryptocurrency holders for procurement,” said Brian Fowler, president of Security First International Holdings, Inc.

“We believe these types of features will help communities to build around lesser known digital currencies and drive more demand.”

The new social activity features will complement the already existing custodian services provided.

Visit http://firstcryptobank.io and get started today.

About Security First Holdings International Inc. (OTC PINK: SCFR)

Security First International Holdings is a company focused on providing innovative financial payment products and services to consumers globally. We provide new possibilities for the digital commerce market through technology and platforms that will create a meaningful financial impact on all consumers.

Savara Announces IND Approval for Expansion of Molgradex Phase 3 Study Into U.S.

AUSTIN, TX—(Marketwired – February 12, 2018) – Savara, Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that the U.S. Food and Drug Administration (FDA) approved its Investigational New Drug (IND) application for Molgradex, an inhaled formulation of recombinant human granulocyte–macrophage colony–stimulating factor (GM–CSF), for the treatment of autoimmune pulmonary alveolar proteinosis, or PAP, allowing for the expansion of the company's Phase 3 IMPALA study into the U.S.

Last year, Savara announced its expedited U.S. development strategy for Molgradex, which enables the ongoing IMPALA study to serve as a pivotal study also for U.S. registration purposes. In support of this strategy, Savara submitted an IND application to the FDA in December 2017 to expand the study into U.S. sites. The IMPALA study is now being conducted in 20 countries globally. The primary endpoint of the study is the alveolar–arterial oxygen gradient, a commonly used measure of oxygenation impairment. In addition, the FDA will focus its review on three key secondary endpoints that will be assessed to determine the amount of improvement in clinical symptoms and function. To help ensure adequate statistical power by confirming or modifying the study sample size, the IND submission also added a blinded interim check of the variability of two of the key secondary endpoints, the six–minute walk distance and St. George's respiratory questionnaire. This blinded analysis indicated that the current sample size of 90 patients is sufficient to achieve 90% power for one of these two endpoints. However, in order to achieve 90% power for both endpoints, and thereby further increase the likelihood of a robust and convincing study outcome, the sample size will be increased to a total of 135 patients, or 45 patients per treatment arm.

“Expansion of the IMPALA study enrollment into the U.S. is an important and exciting step towards a BLA submission of Molgradex in the U.S.,” said Rob Neville, Chief Executive Officer of Savara. “By conducting the interim sample size check we believe we were able to increase the likelihood of success in our sole pivotal study by ensuring a high level of statistical power not only for the primary endpoint, but now also for two key secondary endpoints that the FDA will be focusing on. We have continued strong progress in enrollment, having reached the original target of 90 patients almost two months ahead of schedule, and we expect to complete the revised enrollment target by the third quarter of 2018 and anticipate that top line results will be available in the second quarter of 2019.”

“The IMPALA study is the largest therapeutic study ever conducted in PAP patients, and I am very enthusiastic in participating in this impressive global effort,” said Bruce Trapnell, M.D., Professor of Medicine, and the U.S. Coordinating Principal Investigator of the IMPALA study, at Cincinnati Children's Hospital Medical Center. “Inhaled GM–CSF has shown extremely promising efficacy in earlier academic studies in PAP patients. I believe Molgradex has the potential to transform the treatment of PAP, and considerably reduce or eliminate the need for the invasive whole lung lavage procedures that are the only currently approved treatment option for PAP.”

About the IMPALA Study
The IMPALA study is a randomized, double–blind, placebo–controlled study designed to compare the efficacy and safety of Molgradex with placebo in patients with PAP. The primary endpoint in the IMPALA study is the absolute change from baseline in arterial–alveolar oxygen gradient, a measure of patient's oxygenation status, following 24 weeks of treatment. In addition, the FDA will focus its review on three key secondary endpoints that will be assessed to show improvement in clinical symptoms and function, including six–minute walk distance, St. George's respiratory questionnaire, and the time to need of whole lung lavage. Patients are randomized to receive treatment for 24 weeks in one of three treatment arms: 1) Molgradex 300 µg administered once daily, 2) Molgradex 300 µg and matching placebo administered daily in 7–day intermittent cycles of each, or 3) inhaled placebo administered once daily. Savara now expects that patient enrollment will be completed by the third quarter of 2018, with top line data available in the second quarter of 2019.

About Pulmonary Alveolar Proteinosis (PAP)
Autoimmune PAP is a rare lung disease which is characterized by the build–up of lung surfactant in the alveoli (or air sacs) of the lungs. The surfactant consists of proteins and lipids, and is an important physiological substance that lines the inside of the alveoli to prevent the lungs from collapsing. In a healthy lung, the old and inactivated surfactant is cleared and digested by immune cells called alveolar macrophages. Alveolar macrophages need to be stimulated by GM–CSF to function properly in clearing surfactant, but in autoimmune PAP, GM–CSF is neutralized by antibodies against GM–CSF, rendering the macrophages unable to perform their tasks. As a result, an excess of surfactant accumulates in the alveoli, causing obstruction of gas exchange, and patients start to experience shortness of breath, and decreased exercise tolerance. Patients may also experience chronic cough, as well as episodes of fever, chest pain, or coughing blood, especially if secondary lung infection develops. In the long term, the disease can lead to serious complications, including lung fibrosis and the need for lung transplant.

About Molgradex
Molgradex is an inhaled formulation of recombinant human GM–CSF, in Phase 3 development for PAP and in preparation for Phase 2a development for nontuberculous mycobacteria, or NTM, lung infection. Molgradex is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH). Molgradex has been granted Orphan Drug Designation for the treatment of PAP in the United States and the European Union.

About Savara
Savara Inc. is a clinical–stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life–threatening rare respiratory diseases. Savara's pipeline comprises: Molgradex, an inhaled granulocyte–macrophage colony–stimulating factor, or GM–CSF, in Phase 3 development for PAP, and in preparation for Phase 2a development for NTM lung infection; AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of MRSA infection in Cystic Fibrosis; and, Aironite, an inhaled sodium nitrite for heart failure with preserved ejection fraction, or HFpEF, in Phase 2 development. Savara's strategy involves expanding its pipeline of potentially best–in–class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. Savara's management team has significant experience in orphan drug development and pulmonary medicine, in identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization. More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma)

Forward Looking Statements
Savara cautions you that statements in this press release that are not a description of historical fact are forward–looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward–looking statements may be identified by the use of words referencing future events or circumstances such as “expect,” “intend,” “plan,” “anticipate,” “believe,” and “will,” among others. Such statements include, but are not limited to, statements relating to that the FDA will focus its review on three key secondary endpoints, that to achieve 90% power for both endpoints, and thereby further increase the likelihood of a robust and convincing study outcome, the sample size will be increased to a total of 135 patients, that expansion of the IMPALA study enrollment into the U.S. is an important and exciting step towards a BLA submission of Molgradex in the U.S., that we believe we were able to increase the likelihood of success in our sole pivotal study by ensuring a high level of statistical power not only for the primary endpoint, but now also for two key secondary endpoints, continued strong progress in enrollment, expecting to complete the revised enrollment target by the third quarter of 2018 and anticipate that top line results will be available in the second quarter of 2019, being very enthusiastic in participating in this impressive global effort, belief that Molgradex has the potential to transform the treatment of PAP, and considerably reduce or eliminate the need for the invasive whole lung lavage procedures that are the only currently approved treatment option for PAP, that Savara now expects that patient enrollment will be completed by end of Q3 of 2018, with top line data available by the end of Q2 of 2019 and our strategy. Savara may not actually achieve any of the matters referred to in such forward looking statements, and you should not place undue reliance on these forward–looking statements. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward–looking statements. These forward–looking statements are based upon Savara's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward–looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with the outcome of our ongoing clinical trials for our product candidates (including the expanded IMPALA study), the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient resources for Savara's operations and to conduct or continue planned clinical development programs (including our expanded IMPALA study), the ability to obtain the necessary patient enrollment for our product candidates in a timely manner (including our expanded IMPALA study), the ability to successfully develop our product candidates, the risks associated with the process of developing, obtaining regulatory approval for and commercializing drug candidates such as Molgradex, AeroVanc and Aironite that are safe and effective for use as human therapeutics and the timing and ability of Savara to raise additional equity capital as needed to fund continued operations. All forward–looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of our risks and uncertainties, you are encouraged to review our documents filed with the SEC including our recent filings on Form 8–K, Form 10–K and Form 10–Q. You are cautioned not to place undue reliance on forward–looking statements, which speak only as of the date on which they were made. Savara undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.